Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893645 | 0.89 | MGLL (0.50) | MGLLMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL12919544 | 0.86 | MGLL (0.47) | MGLLMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL12893655 | 0.85 | MGLL (0.49) | MGLLMAPTCCR5MEN1KMT2A | |
| SCHEMBL12893501 | 0.84 | MGLL (0.68) | MGLLMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL14467272 | 0.83 | MGLL (0.52) | MGLLMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL12893511 | 0.77 | AKR1C3 (0.46) | MGLLMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL13391460 | 0.77 | CYP3A4 (0.54) | MAPTCYP3A4KDM4E | |
| SCHEMBL14355764 | 0.77 | CYP3A4 (0.54) | MAPTCYP3A4KDM4E | |
| SCHEMBL13391090 | 0.77 | LSS (0.50) | CYP3A4KDM4EAKR1C3 | |
| SCHEMBL13391433 | 0.77 | CYP3A4 (0.54) | MAPTCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879880-B2 | such as [4-[(2-aminopyridin-4-yl)methyl]piperazin-1-yl]-[4-(pyridin-4-ylamino)phenyl]methanone, used for the treatment of inflammatory diseases, allergic conditions, diabetes, obesity, metabolic syndrome, cognition disorder, cardiovascular and nervous system disorders | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | HRH3, CHRM2, HCRTR2 | MGLL 414/4885MAPT 1609/4885CCR5 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.